|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product sales, net | |||||
| Royalties and contract revenues | |||||
| Total revenues | |||||
| Operating expenses: | |||||
| Cost of product sales (excluding amortization of acquired developed technologies) | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Intangible asset amortization | |||||
| Acquired in-process research and development | |||||
| Intangible asset impairment charge | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Interest expense, net | |||||
| Foreign exchange gain (loss) | |||||
| Income (loss) before income tax benefit and equity in loss of investees | |||||
| Income tax benefit | |||||
| Equity in loss of investees | |||||
| Net income (loss) | |||||
| Net income (loss) per ordinary share: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | |||||
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) |
Loading...